IMC Logo.jpg
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
October 04, 2024 06:30 ET | Immuron Limited
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two...
IMM-529 Mechanism of Action - Clostridioides difficile Infection (CDI)
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024 11:54 ET | Immuron Limited
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on...
IMC Logo.jpg
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
August 16, 2024 06:00 ET | Immuron Limited
Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16,...
IMC Logo.jpg
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
August 15, 2024 18:14 ET | Immuron Limited
MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...
IMC Logo.jpg
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
August 07, 2024 06:00 ET | Immuron Limited
MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be...
IMC Logo.jpg
Immuron announces record Travelan® sales globally, Australia and USA
July 15, 2024 08:00 ET | Immuron Limited
Sales Highlights: Global• FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp)  • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter    Australia• FY 2024 AUD$3.7...
IMM-529 MOA in CDI - Targets Spores, Vegetative Cells, and Toxin B
Immuron requests pre-IND meeting for IMM-529 with FDA filing
July 02, 2024 06:00 ET | Immuron Limited
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that...
IMC Logo.jpg
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
June 05, 2024 06:00 ET | Immuron Limited
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that...
IMC Logo.jpg
Immuron CEO Steven Lydeamore to present at Peak Sky High
May 31, 2024 06:00 ET | Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief...
IMC Logo.jpg
Immuron Board Changes
May 31, 2024 06:00 ET | Immuron Limited
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston...